博九娱乐网

BeiGene is a global, commercial-stage biotechnology company focused on discovering, developing, manufacturing, and commercializing innovative medicines to improve treatment outcomes and access for patients worldwide. Their 4,200+ employees in China, the United States, Australia, Europe, and elsewhere are committed to expediting the development of a diverse pipeline of novel therapeutics…More. They currently market two internally discovered oncology products: BTK inhibitor BRUKINSA庐 (zanubrutinib) in the United States and China, and anti-PD-1 antibody tislelizumab in China. They also market or plan to market in China additional oncology products licensed from Amgen Inc., Celgene Logistics S脿rl, a Bristol Myers Squibb (BMS) company, and EUSA Pharma.